US 11,667,915 B2
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
Tod M. Woolf, Sudbury, MA (US); Joanne Kamens, Newton, MA (US); William Salomon, Worcester, MA (US); and Anastasia Khvorova, Westborough, MA (US)
Assigned to Phio Pharmaceuticals Corp., Marlborough, MA (US)
Filed by Phio Pharmaceuticals Corp., Marlborough, MA (US)
Filed on Nov. 11, 2019, as Appl. No. 16/680,101.
Application 16/680,101 is a continuation of application No. 15/638,586, filed on Jun. 30, 2017, granted, now 10,479,992.
Application 15/638,586 is a continuation of application No. 13/147,882, granted, now 9,745,574, previously published as PCT/US2010/000348, filed on Feb. 4, 2010.
Claims priority of provisional application 61/163,306, filed on Mar. 25, 2009.
Claims priority of provisional application 61/150,582, filed on Feb. 6, 2009.
Claims priority of provisional application 61/149,968, filed on Feb. 4, 2009.
Prior Publication US 2020/0308578 A1, Oct. 1, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/11 (2006.01)
CPC C12N 15/111 (2013.01) [C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3515 (2013.01); C12N 2310/3519 (2013.01); C12N 2310/533 (2013.01); C12N 2320/51 (2013.01)] 20 Claims
 
1. An isolated double stranded nucleic acid molecule comprising a guide strand and a passenger strand, wherein the passenger strand is 8-18 continuous nucleotides in length, wherein the guide strand is 16-28 nucleotides in length, wherein the double stranded nucleic acid molecule comprises a double stranded region and a single stranded region, wherein the double stranded region is 8-18 nucleotides in length and is connected through a cleavable chemical linker to the single stranded region, and wherein the single stranded region comprises at least six phosphorothioate modified nucleotides.